1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Delayed Nasdaq  -  04:00 2022-06-30 pm EDT
142.85 USD   +0.03%
05:34pUS FDA wants COVID boosters targeting Omicron BA.4, BA.5 subvariants
RE
04:40pTweaked COVID boosters in US must target newer omicron types
AQ
04:36pModerna Seeks Health Canada Nod For New Double-Protection Covid-19 Booster - Global News
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna, International AIDS Vaccine Initiative to Start Volunteer Screening for Phase 1 HIV Vaccine Trial in Africa

05/18/2022 | 08:10am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
DOW JONES AFRICA TITANS 50 INDEX -1.33% 447.07 Real-time Quote.-15.38%
DOW JONES SOUTH AFRICA(ZAR) 0.00% 1858.13 Real-time Quote.-4.58%
IMMUNOGEN, INC. 3.21% 4.5 Delayed Quote.-39.35%
MODERNA, INC. 0.03% 142.85 Delayed Quote.-43.76%
S&P AFRICA 40 INDEX -0.04% 143.83 Real-time Quote.-16.23%
All news about MODERNA, INC.
05:34pUS FDA wants COVID boosters targeting Omicron BA.4, BA.5 subvariants
RE
04:40pTweaked COVID boosters in US must target newer omicron types
AQ
04:36pModerna Seeks Health Canada Nod For New Double-Protection Covid-19 Booster - Global New..
RE
02:22pCOVID SCIENCE-Pausing methotrexate improves booster response; first-trimester of pregna..
RE
06/29BioNTech, Pfizer to starting testing universal coronavirus vaccine in H2
RE
06/29Taiwan to receive first doses of Novavax COVID vaccine this week
RE
06/28Pfizer, Moderna to be ready with BA.1-specific COVID boosters
RE
06/28FDA advisers recommend updating COVID booster shots for fall
AQ
06/27INSIDER SELL : Moderna
MT
06/27US grapples with whether to modify COVID vaccine for fall
AQ
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 22 079 M - -
Net income 2022 11 509 M - -
Net cash 2022 18 531 M - -
P/E ratio 2022 5,24x
Yield 2022 -
Capitalization 56 820 M 56 820 M -
EV / Sales 2022 1,73x
EV / Sales 2023 3,48x
Nbr of Employees 2 700
Free-Float 90,6%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 142,85 $
Average target price 213,67 $
Spread / Average Target 49,6%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-43.76%56 804
IQVIA HOLDINGS INC.-24.11%40 527
LONZA GROUP AG-33.77%39 234
SEAGEN INC.15.82%32 961
CELLTRION, INC.-9.85%18 726
ICON PUBLIC LIMITED COMPANY-29.85%17 663